Ionis Pharmaceuticals reports positive topline Phase 3 FUSION results for ulefnersen in FUS-ALS

Ionis Pharmaceuticals announced positive topline results from its Phase 3 FUSION study of ulefnersen, calling it a significant milestone toward the first potential disease-modifying treatment for FUS-ALS.

Detected & updated continuously · Source: Nebula